Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD4635 + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD4635||AZD 4635|AZD-4635||Adenosine Targeting 18||AZD4635 binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02740985||Phase I||AZD4635 AZD4635 + Durvalumab||A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies||Recruiting|
|NCT04089553||Phase II||AZD4635 + Durvalumab AZD4635 + Oleclumab||An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer||Recruiting|
|NCT04495179||Phase II||AZD4635 + Durvalumab AZD4635 + Cabazitaxel + Durvalumab||A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (AARDVARC)||Not yet recruiting|